A review of binimetinib for the treatment of mutant cutaneous melanoma.

Article Details

Citation

Copy to clipboard

Koelblinger P, Dornbierer J, Dummer R

A review of binimetinib for the treatment of mutant cutaneous melanoma.

Future Oncol. 2017 Aug;13(20):1755-1766. doi: 10.2217/fon-2017-0170. Epub 2017 Jun 7.

PubMed ID

28587477 [ View in PubMed

]

Abstract

Although significant progress has been made in the treatment of unresectable or metastatic melanoma, at least half of all advanced melanoma patients eventually progress and pass away due to their disease. In particular, patients with NRAS-mutated melanoma still face limited therapeutic options, with immunotherapy being the current treatment type of choice. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. The results of a recent Phase III trial rendered binimetinib the first targeted therapy agent to significantly improve progression-free survival in NRAS-mutated melanoma. This review will summarize the development and clinical data of binimetinib in melanoma in general and also explore the potential future role of this substance as single agent or combination therapy.

DrugBank Data that Cites this Article

Drugs

Binimetinib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Binimetinib	Dual specificity mitogen-activated protein kinase kinase 2	Protein	Humans	Yes	Inhibitor	Details